A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer

Trial Profile

A Phase 2 Study of Atezolizumab (MPDL3280A) in Combination With Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer

Suspended
Phase of Trial: Phase II

Latest Information Update: 03 Oct 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab
  • Indications Cervical cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Sep 2017 Status changed from recruiting to suspended due to scheduled interim monitoring
    • 15 Jun 2017 Status changed from suspended to recruiting.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top